Regulatory Development of Flavocide
Filed with ASX · · 9 pages · English
Summary by 6ix AI
Bio-Gene Technology Ltd. has announced progress in the regulatory development of Flavocide, including a timeline for its first regulatory submission. The development program and toxicology studies for Flavocide are advancing well, with initial studies supporting further testing. The company aims to submit its application for registration of Flavocide as a new active constituent with the APVMA in the near future. This update outlines the studies required for regulatory approval and the expected timelines for submission and results.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Bio-Gene Technology Ltd. on 6ix
Story so far
Earlier from Bio-Gene Technology
- Appendix 4D and Half-Year Accounts 31 December 2025
- Quarterly Activities/Appendix 4C Cash Flow Report
- U.S. Department of Defense Grant Programs Advance
- Bio-Gene Receives $519,500 R&D Tax Incentive
- CEO's Presentation
Later from Bio-Gene Technology
- Sumitomo & Nakashima to launch Qcide products in Japan
- Results of Placement
- Appendix 4E and 2026 Annual Report
Follow Bio-Gene Technology into a list and get an email when it puts out news.
Follow Bio-Gene Technology